Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26246644 | 0.79 | GAA (0.47) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8373773 | 0.79 | ALDH1A1 (0.40) | GAARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20851370 | 0.79 | GAA (0.47) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13218447 | 0.79 | GAA (0.47) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3448499 | 0.79 | PDE10A (0.41) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL3485651 | 0.79 | RAB9A (0.48) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL15004601 | 0.79 | RAB9A (0.38) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL8811947 | 0.79 | KMT2A (0.39) | GAARAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL542463 | 0.79 | NPC1 (0.37) | GAAMAPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL7845934 | 0.79 | NPSR1 (0.36) | GAAMAPTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406808-A1 | DEHYDRATION OF LACTIC ACID AND RELATED COMPOUNDS IN SOLID ACIDS VIA MULTIFUNCTIONAL FLEXIBLE MODIFIERS | NATIONAL SCIENCE FOUNDATION | 2023-12-21 | — | — | US | disclosed |
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3744721-A1 | CONDENSED CYCLIC COMPOUND HAVING DOPAMINE D3 RECEPTOR ANTAGONISM | Shionogi & Co., Ltd (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-07-30 | — | — | US | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| EP-3036235-B1 | NEW BIS-AMIDO PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-04-19 | — | — | EP | disclosed |
| US-20160190477-A1 | ORGANIC ELECTROLUMINESCENCE COMPOSITION, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, SOLUTION OF MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ORGANIC ELECTROLUMINESCENCE ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
| US-20160190477-A1 | ORGANIC ELECTROLUMINESCENCE COMPOSITION, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, SOLUTION OF MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ORGANIC ELECTROLUMINESCENCE ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
| EP-3036235-A1 | NEW BIS-AMIDO PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-9249151-B2 | Bis-amido pyridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GAA 4210/4885MAPT 4174/4885RAB9A 2891/4885 |
| US-20200239439-A1 | HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME | CXCR4, CXCL12, CXCR1 | GAA 2222/4885MAPT 3307/4885RAB9A 522/4885 |
| US-20210040117-A1 | CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT | DRD3, DRD2, DRD1 | GAA 4530/4885MAPT 4238/4885RAB9A 692/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | GAA 2837/4885MAPT 2117/4885RAB9A 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.